N Katsumata

Summary

Affiliation: National Cancer Center
Country: Japan

Publications

  1. pmc Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chem
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center, Tokyo, Japan
    Jpn J Clin Oncol 38:777-85. 2008
  2. pmc Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, 104 0045 Tokyo, Japan
    Br J Cancer 93:999-1004. 2005
  3. doi Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 20:1210-5. 2009
  4. pmc Docetaxel: an alternative taxane in ovarian cancer
    N Katsumata
    Department of Medical Oncology, National Cancer Centre Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 89:S9-S15. 2003
  5. doi Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Lancet 374:1331-8. 2009
  6. pmc Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 22:1353-7. 2011
  7. doi Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy
    K Hashimoto
    Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 21:2195-200. 2010
  8. pmc Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
    M Tanioka
    Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 103:297-302. 2010
  9. ncbi Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy
    S Akashi-Tanaka
    Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Int J Cancer 96:66-73. 2001
  10. doi FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
    K Tamura
    Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 22:1302-7. 2011

Detail Information

Publications41

  1. pmc Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chem
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center, Tokyo, Japan
    Jpn J Clin Oncol 38:777-85. 2008
    ..This study was conducted to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in Japanese patients with Müllerian carcinoma having a therapeutic history of platinum-based chemotherapy...
  2. pmc Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, 104 0045 Tokyo, Japan
    Br J Cancer 93:999-1004. 2005
    ....
  3. doi Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 20:1210-5. 2009
    ..This randomized, multicenter, phase III trial compared doxorubicin plus cyclophosphamide (AC), single-agent docetaxel (D), and an alternating regimen of AC and docetaxel (AC-D) as first-line chemotherapy in metastatic breast cancer (MBC)...
  4. pmc Docetaxel: an alternative taxane in ovarian cancer
    N Katsumata
    Department of Medical Oncology, National Cancer Centre Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 89:S9-S15. 2003
    ....
  5. doi Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Lancet 374:1331-8. 2009
    ..Attempts to improve patient survival by including other drugs have yielded disappointing results. We compared a conventional regimen of paclitaxel and carboplatin with a dose-dense weekly regimen in women with advanced ovarian cancer...
  6. pmc Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 22:1353-7. 2011
    ..S-1 is an oral fluoropyrimidine. This phase II study was designed to evaluate the efficacy and safety of S-1 in patients with advanced or recurrent uterine cervical cancer...
  7. doi Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy
    K Hashimoto
    Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 21:2195-200. 2010
    ..The aim of this study was to develop a prediction model of progressive disease (PD) in breast cancer patients without measurable disease in first-line chemotherapy...
  8. pmc Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
    M Tanioka
    Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 103:297-302. 2010
    ..This study was designed to identify factors predictive of recurrence in patients with pCR...
  9. ncbi Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy
    S Akashi-Tanaka
    Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Int J Cancer 96:66-73. 2001
    ..In conclusion, CE-CT is the most accurate noninvasive technique for identifying the extent of the residual carcinoma after neoadjuvant chemotherapy if cases of IBC and ILC are excluded...
  10. doi FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
    K Tamura
    Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Ann Oncol 22:1302-7. 2011
    ..This prospective phase II trial aimed to evaluate whether these polymorphisms are associated with clinical efficacies in patients who received trastuzumab...
  11. doi Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients
    T Hirata
    Dept of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo 104 0045, Japan
    Eur Respir J 38:1425-30. 2011
    ..24. Our results suggest that the efficacy of P-ST may be superior to that of ST alone with respect to local control of pleural effusions in breast cancer patients...
  12. doi Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)
    H Nomura
    Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan
    Ann Oncol 22:636-42. 2011
    ..The purpose of this study is to assess the efficacy and safety of treatment with taxane plus platinum in combination therapies for advanced or recurrent endometrial carcinoma...
  13. pmc Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
    K Yonemori
    Breast and Medical Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 100:50-5. 2009
    ..Therefore, the regimen may be one of the potentially available chemotherapeutic options for community standard of care in patients with a good performance status...
  14. ncbi A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study
    N Katsumata
    National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 11:1531-6. 2000
    ..This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in Japanese patients with advanced ovarian cancer...
  15. ncbi Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: Japanese Gynecologic Oncology Group trial (JGOG2041)
    H Nomura
    Japanese Gynecologic Oncology Group School of Medicine Keio University, Tokyo, Japan Kitasato University School of Pharmaceutucal Science, Tokyo, Japan National Cancer Center Hospital, Tokyo, Japan Kinki University School of Medicine, Osaka, Japan Kyoto University Graduate School of Medicine, Kyoto, Japan Social Insurance Sagamino Hospital, Sagamihara, Japan Kagoshima City Hospital, Kagoshima, Japan Shikoku Cancer Center, Matsuyama, Japan Tohoku University Graduate School of Medicine, Sendai, Japan Japanese Gynecologic Oncology Group
    J Clin Oncol 26:16526. 2008
    ..16526 Background: The purpose of this study is to assess the efficacy and safety of treatment with taxane plus platinum in combination therapies for advanced or recurrent endometrial carcinoma...
  16. doi Clinical characteristics and outcomes of women with stage IV endometrial cancer
    M Tanioka
    Division of Breast and Medical Oncology, National Cancer Center Hospital Tokyo, Tsukiji 5 1 1, Chuo Ku, Tokyo, Japan
    Med Oncol 27:1371-7. 2010
    ..In women with stage IV EC, histologic features and extent of disease are more important determinants of outcomes than any kind of treatment. The indication for surgery should be carefully considered in this subset of patients...
  17. ncbi What factors affect the place of end-of-life care for patients with metastatic breast cancer?
    K Harano
    National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 29:218. 2011
    ..The purpose of this study is to identify factors that affect the place of EOL care in patients with metastatic breast cancer in Japan...
  18. ncbi Secondary platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy
    M Tanioka
    National Cancer Center Hospital Japan, Tokyo, Japan
    J Clin Oncol 27:5588. 2009
    ..We therefore evaluated the relative influence of platinum free interval ( PFI ) between the completion of front-line regimen and the institution of second-line regimen...
  19. ncbi Phase II study of carboplatin (CBDCA) and irinotecan (CPT-11) for patients with cancer of unknown primary (CUP)
    M Ando
    National Cancer Center Hospital, Tokyo, Japan Yokohama Industrial Accidents Hospital, Kanagawa, Japan
    J Clin Oncol 26:13514. 2008
    ..13514 Background: Optimal chemotherapeutic-regimen for CUP without favorable prognostic- factors is uncertain. Platinum containing regimens are widely used for those patients...
  20. ncbi Evaluation of tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis as predictive markers for response to neoadjuvant chemotherapy in triple-negative breast cancer
    M Ono
    National Cancer Center Hospital, Tokyo, Japan National Defence Medical College, Tokyo, Japan National Cancer Center Research Institute, Tokyo, Japan
    J Clin Oncol 27:559. 2009
    ..We examined the value of histological parameters including tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis as surrogate markers for pCR in TNBC...
  21. ncbi Feasibility of vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy for adult rhabdomyosarcoma (RMS) with regard to dose intensity (DI)
    Y Kojima
    National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 29:10083. 2011
    ..Herein, we examined whether the administration of VAC chemotherapy for adult RMS is feasible with regard to the DIs of V and C...
  22. ncbi Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance
    M Ando
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 19:336-42. 2001
    ..The status of anthracycline resistance is important for the prediction of response to second-line treatment with docetaxel...
  23. pmc A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer
    M Ando
    Department of Medicine, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 77:1937-43. 1998
    ..The recommended doses of docetaxel and 5-day continuous infusion of 5-FU for a phase II trial are 50 mg m(-2) and 500 mg m(-2) per day every 3 or 4 weeks...
  24. doi Compliance with Good Clinical Practice in oncology registration trials in Japan
    K Yonemori
    Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo 103 0045, Japan
    Ann Oncol 22:1451-6. 2011
    ....
  25. ncbi Feasibility of weekly paclitaxel/carboplatin for ovarian or peritoneal cancer patients with poor performance status
    M Yunokawa
    National Cancer Center, Tokyo, Japan
    J Clin Oncol 26:16567. 2008
    ..16567 Background: To assess the feasibility of weekly paclitaxel/ carboplatin as a first line chemotherapy among poor performance status (PS) patients (pts) with advanced ovarian or peritoneal cancer...
  26. ncbi Phase II study of S-1 in patients with advanced or recurrent cervical cancer
    Y Hirai
    Cancer Institute Hospital, Tokyo, Japan National Cancer Center Hospital, Tokyo, Japan Osaka Medical Center for Cancer and Cardiovascular, Osaka, Japan Iwate Medical University, Morioka, Japan Wakayama Medical University Hospital, Wakayama, Japan Kagoshima City Hospital, Kagoshima, Japan Hyogo Cancer Center, Akashi, Japan The Jikei University, School of Medicine, Tokyo, Japan
    J Clin Oncol 26:5514. 2008
    ..This phase II study was designed to evaluate the efficacy and safety of S-1 in uterine cervical cancer. This is the first clinical study of S-1 in gynecologic cancer...
  27. ncbi Existence of blood brain barrier in brain metastases with breast cancer
    M Ono
    National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 26:13513. 2008
    ..We examine expression and localization of BBB with representative immunohistochemical markers of glucose transporter 1 (Glut-1) and breast cancer resistance protein (BCRP) in brain metastases with breast cancer patients...
  28. ncbi Correlation of FcγR IIa-H131R and IIIa-V158F polymorphisms and clinical outcome of trastuzumab in both neoadjuvant and metastatic setting in patients with HER-2 positive breast cancer
    K Tamura
    National Cancer Center Hospital, Tokyo, Japan Shikoku Cancer Center, Matsuyama, Japan Kinki University School of Medicine, Osaka, Japan
    J Clin Oncol 27:1100. 2009
    ....
  29. ncbi Long-term prognostic factors of node-negative invasive breast cancer of luminal subtype: A comparison between histologic grades and molecular markers including Ki-67 and HER2
    M Ono
    National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 29:e11050. 2011
    ..In the present study, we retrospectively compared the prognostic impact of Ki67 and histological/nuclear grade in 560 cases surgically resected between 1996 and 2000 in a single hospital...
  30. ncbi Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin
    T Takahashi
    Breasr Surgery Division, National Cancer Hospital, Tokyo, Japan
    Breast Cancer 8:234-7. 2001
    ..There were 4 cases of IBC and one case of SCC of the breast who received neoadjuvant chemotherapy in this series. Our observations suggest that this regimen might not be effective for these types of breast cancer...
  31. ncbi Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated with vincristine, dactinomycin, and cyclophosphamide (VAC)/VAC-like chemotherapy
    K Harano
    National Cancer Center Hospital, Tokyo, Japan Department of Management Science, Graduate School of Engineering Tokyo University of Science, Tokyo, Japan
    J Clin Oncol 29:10092. 2011
    ..The purpose of the current study is to compare the clinical outcomes of adult RMS to childhood RMS by local or metastatic disease, to examine the impact of local therapy, and the optimal timing of local therapy in metastatic disease...
  32. ncbi Which factors will make the duration short between last palliative chemotherapy and death?
    K Hashimoto
    National Cancer Center Hospital, Tokyo, Japan Kitasato University, School of Pharmaceuticals, Tokyo, Japan
    J Clin Oncol 26:20575. 2008
    ....
  33. pmc Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)
    N Katsumata
    Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital, Kawasaki, Japan
    Br J Cancer 108:1957-63. 2013
    ..A phase III trial was conducted to determine whether neoadjuvant chemotherapy (NACT) before radical surgery (RS) improves overall survival...
  34. doi Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor
    N Katsumata
    Department of Medical Oncology, Nippon Medical School, Musashikosugi Hospital, 1 396 Kosugi machi, Nakahara ku, Kawasaki City, Kanagawa Prefecture, Japan
    Ann Oncol 22:viii29-viii32. 2011
    ..0015], as was the overall survival at 3 years (72.1% versus 65.1%; HR 0.75; 95% CI: 0.57-0.98; P=0.03). Dose-dense weekly paclitaxel plus carboplatin represents a new treatment option in women with advanced epithelial ovarian cancer...
  35. ncbi Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancer
    N Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Cancer Chemother Pharmacol 43:441-4. 1999
    ..In order to clinically confirm these promising preclinical observations, we performed a phase II trial of KRN8602 in patients with anthracycline-resistant metastatic breast cancer...
  36. ncbi Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology
    S Isonishi
    Jikei University School of Medicine, Tokyo, Japan Kitasato University, Tokyo, Japan National Cancer Center Hospital, Tokyo, Japan Kousei General Hospital, Tokyo, Japan Keio University, Tokyo, Japan Social Insurance Sagamino Hospital, Sagamihara, Japan Tokyo Medical University, Tokyo, Japan Osaka City General Hospital, Osaka, Japan Iwate Medical University, Morioka, Japan
    J Clin Oncol 26:5506. 2008
    ..We compared the c-TC with dose dense weekly administration with TC (dd-TC) as first-line chemotherapy for stage II-IV epithelial ovarian, fallopian tube or primary peritoneal cancer...
  37. pmc Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus
    T Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 88:245-50. 2003
    ....
  38. ncbi Mental adjustment to first recurrence and correlated factors in patients with breast cancer
    Y Okano
    Psycho Oncology Division, National Cancer Center Research Institute East, Chiba, Japan
    Breast Cancer Res Treat 67:255-62. 2001
    ....
  39. pmc Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer
    T Hirata
    Department of Breast and Medical Oncology, National Cancer Center Hospital, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 101:1529-36. 2009
    ..To evaluate the impact of change in the hormone receptor (HR) status (HR status conversion) on the long-term outcomes of breast cancer patients treated with neoadjuvant chemotherapy (NAC)...
  40. ncbi Three novel PHEX gene mutations in Japanese patients with X-linked hypophosphatemic rickets
    K Sato
    Department of Pediatrics, Hokkaido University School of Medicine, N15, W7, Kita ku, Sapporo, Japan 060 8638
    Pediatr Res 48:536-40. 2000
    ..These results suggest that: 1) PHEX gene mutations are responsible for XLH in Japanese patients, and 2) PHEX gene mutations are heterogeneous in the Japanese population similarly to other ethnic populations...
  41. ncbi Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208
    Yutaka Tokuda
    Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259 1193, Japan
    Cancer Sci 99:145-51. 2008
    ..78). Although the prespecified values of the two arms were not so accurate as to allow detection of the observed difference, no advantage of HDC was observed in terms of RFS or overall survival...